Sample Mislabeling: Prevention Strategies with Risk-Based Oversight

Introduction: Why Mislabeling is a Critical GCP Violation

Sample mislabeling in clinical trials can result in compromised data integrity, participant risk, protocol deviations, and regulatory inspection findings. Regulatory bodies such as the FDA, EMA, and MHRA consider incorrect, incomplete, or missing sample identifiers as serious non-compliances that threaten subject protection and trial validity.

This article presents risk-based strategies to prevent sample mislabeling in clinical trials. It outlines best practices in SOPs, label design, verification steps, and CAPA management from global regulatory inspections.

What Constitutes Sample Mislabeling?

According to ICH-GCP and FDA expectations, mislabeling can include:

• Incorrect Subject ID or Protocol Number on the sample
• Omission of collection date/time or sample type
• Use of handwritten or faded labels not matching CRF data
• Mismatch between tube content and indicated label
• Duplicate labels used on multiple specimens

These errors may cause rejection of samples by central labs, and their consequences are rarely reversible.

Risk Factors for Sample Labeling Errors

Mislabeling incidents typically stem from one or more of the following:

• Manual label writing in high-volume or fast-paced sites
• Ambiguous SOPs with non-standard label templates
• Failure to cross-verify labels before packaging
• High staff turnover or inadequate training
• Uncalibrated or outdated label printers

Prevention Through Labeling SOP Design

An FDA-compliant SOP must include:

• Standardized label templates with required fields (Subject ID, Visit #, Sample Type)
• Instruction on pre-printing labels or use of validated printers
• Procedure for dual verification (two-person check)
• Process for correction or replacement of damaged labels
• Audit trail for all labels used, destroyed, or replaced

Case Study: Central Lab Rejects Due to Label Overlap

In a global respiratory trial, the central lab rejected 10% of samples due to barcode overlaps—two samples bore identical codes because the label printer template was not locked and staff accidentally reused an old code set.

CAPA Actions:

• Immediate halt in sample shipment
• Label printer software locked and reconfigured
• Re-training of all staff on sample ID rules
• Corrective labeling SOP introduced
• 100% audit of prior samples at high-risk sites

Table: Labeling Verification Checklist

Risk-Based Oversight in Labeling

Sponsors and CROs are expected to implement risk-based oversight in labeling processes:

• Include label verification in Site Initiation Visit (SIV) checklist
• Perform targeted monitoring based on prior labeling deviation rates
• Flag high-risk sites with high sample volumes or new staff
• Introduce Source Data Verification (SDV) focusing on labeling logs
• Utilize central lab feedback to detect trends in labeling errors

Training Modules for Site Staff

Key elements of training on labeling include:

• Hands-on demonstration of labeling steps using mock samples
• Barcode scanning simulation
• Training on handling damaged or duplicate labels
• Instruction on label printing tools and error messages
• Review of sample rejection cases and associated CAPA

External Reference

Sample labeling methods and rejection rates are often reported in ClinicalTrials.gov protocol documents and sponsor disclosures, which can offer benchmarks for acceptable labeling practices.

Conclusion

Sample mislabeling is not just a minor clerical error—it is a major risk to trial validity, regulatory compliance, and patient safety. Through clear SOPs, strong training, robust verification, and risk-based monitoring, sponsors and investigators can minimize labeling errors. Implementing a proactive CAPA framework and incorporating lessons from real-world audits are essential to sustaining compliance.